IDEAYA Biosciences, Inc.
IDYA
$24.82
-$0.04-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.00M | 7.00M | 7.00M | 3.92M | 11.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00M | 7.00M | 7.00M | 3.92M | 11.96M |
| Cost of Revenue | 342.45M | 322.75M | 294.67M | 193.26M | 169.81M |
| Gross Profit | -335.45M | -315.75M | -287.67M | -189.34M | -157.85M |
| SG&A Expenses | 48.78M | 44.59M | 39.30M | 35.42M | 33.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 391.23M | 367.35M | 333.98M | 228.68M | 203.35M |
| Operating Income | -384.23M | -360.35M | -326.98M | -224.75M | -191.39M |
| Income Before Tax | -331.80M | -307.08M | -274.48M | -178.12M | -153.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -331.80 | -307.08 | -274.48 | -178.12 | -153.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -331.80M | -307.08M | -274.48M | -178.12M | -153.74M |
| EBIT | -384.23M | -360.35M | -326.98M | -224.75M | -191.39M |
| EBITDA | -381.76M | -357.98M | -324.59M | -222.31M | -188.88M |
| EPS Basic | -3.79 | -3.59 | -3.30 | -2.33 | -2.18 |
| Normalized Basic EPS | -2.53 | -2.41 | -2.23 | -1.56 | -1.47 |
| EPS Diluted | -3.79 | -3.59 | -3.30 | -2.33 | -2.18 |
| Normalized Diluted EPS | -2.53 | -2.41 | -2.23 | -1.56 | -1.47 |
| Average Basic Shares Outstanding | 350.36M | 339.85M | 326.60M | 304.51M | 278.32M |
| Average Diluted Shares Outstanding | 350.36M | 339.85M | 326.60M | 304.51M | 278.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |